Antitumor Activity of G3139 Lipid Nanoparticles (LNPs)

详细信息    查看全文

• 作者：Xiaogang Pan ; Li Chen ; Shujun Liu ; Xiaojuan Yang ; Jian-Xin Gao ; Robert J. Lee
• 刊名：Molecular Pharmaceutics
• 出版年：2009
• 出版时间：February 2, 2009
• 年：2009
• 卷：6
• 期：1
• 页码：211-220
• 全文大小：388K
• 年卷期：v.6,no.1(February 2, 2009)
• ISSN：1543-8392

文摘

G3139, an antisense oligodeoxyribonucleotide (ODN) against Bcl-2, contains two CpG dinucleotides and has shown immunostimulatory activities in preclinical studies. It has been suggested that immunoactivation, rather than antisense activity, is primarily responsible for the therapeutic efficacy of G3139. Nanoparticle formulations naturally target phagocytic antigen presenting cells and therefore might enhance the immunological effects of G3139. In this study, a novel formulation of lipid nanoparticles (LNPs) encapsulating G3139 was synthesized and evaluated in mice bearing L1210 subcutaneous tumors. Intravenous injection of G3139-LNPs into mice led to increased serum levels of IL-6 and IFN-γ, promoted proliferation of natural killer (NK) cells and dendritic cells (DCs), and triggered a strong antitumor immune response in mice. The observed effects were much greater than those induced by free G3139. Correspondingly, the G3139-LNPs more effectively inhibited tumor growth and induced complete tumor regression in some mice. In contrast, free G3139 was ineffective in tumor growth inhibition and did not prolong survival of the tumor-bearing mice. These results suggest that G3139-LNPs are a potential immunomodulatory agent and may have applications in cancer therapy.